Beta Drugs
BETA NSE
Beta Drugs
HealthcareNSE: BETA Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,283 Cr
Volatility
Moderate
P/E Ratio
48.49
EBITDA
₹75.68 Cr
Return on Equity
21.52%
Debt to Equity
0.6
Book Value
₹221.65
52W High
₹2,807.9
52W Low
₹990.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Stock is trading at 8.77 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.53%
Growth Rate
Revenue Growth
4.35% lower than
3Y
Net Income Growth
-2.17% lower than
3Y
Cash Flow Change
16.84% lower than
3Y
ROE
-7.2% lower than
3Y
ROCE
-36.99% higher than
3Y
EBITDA Margin (Avg.)
-13.02% lower than
3Y
Quarterly Results
| Particulars | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 |
| PBT | 12 | 12 | 16 | 16 | 10 | 12 | 22 |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.4 | 8.93 | 14.25 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 | 410 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 | 327 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 83 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 10 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 15 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| PBT | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 61 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | 24% | — |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 46 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.6 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 | 43.69 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Investing | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Financing | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 | -22 |
| Free Cash Flow | 9 | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
| CFO/OP | 181 | 1 | 47 | 75 | 69 | 44 | 52 | 48 | 49 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 | 113 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 | 97 |
| ROCE % | — | 18% | 21% | 22% | 36% | 34% | 33% | 27% | 19% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Beta Drugs insights
63 extracted metrics + investor summaries across FY18–FY27.
Documents
1
Board Meeting - Intimation
31 Aug - BETA DRUGS LIMITED has informed about Board Meeting to be held on 03-Sep-2026 to consider Other business. 31 Aug - BETA DRUGS LIMITED has informed about Board Meeting to be held on 03-Sep-2026 to consider Other business.
2
Board Meeting - Other business matters
31 Aug - Board meeting on 3 September 2026 to fix 21st AGM, approve notice and FY26 Directors’ Report. 31 Aug - Board meeting on 3 September 2026 to fix 21st AGM, approve notice and FY26 Directors’ Report.
3
Clarification - Financial Results
22 Jul - Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On … 22 Jul - Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
4
Copy of Newspaper Publication
21 Jul - Beta Drugs published Q1 FY27 unaudited standalone and consolidated results on 21 July 2026. 21 Jul - Beta Drugs published Q1 FY27 unaudited standalone and consolidated results on 21 July 2026.
5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
9h - Allotment of equity shares under ESOP scheme of the Bank 9h - Allotment of equity shares under ESOP scheme of the Bank
Frequently Asked Questions about Beta Drugs
What does Beta Drugs Ltd do?
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]
Where is Beta Drugs Ltd (BETA) listed?
Beta Drugs Ltd trades as BETA on the NSE.
Which sector does Beta Drugs Ltd belong to?
Beta Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Beta Drugs Ltd?
Beta Drugs Ltd has a market capitalisation of ₹2,283 Cr, which places it in the Small Cap band.
What is the PE ratio of Beta Drugs Ltd?
Beta Drugs Ltd trades at a PE ratio of 48.49, against a book value of ₹221.65 per share.
What is the 52-week high and low of Beta Drugs Ltd?
Over the last 52 weeks Beta Drugs Ltd has traded between ₹990.1 and ₹2,807.9.
What is the Return on Equity (ROE) of Beta Drugs Ltd?
Beta Drugs Ltd reported a return on equity of 21.52%. Its debt-to-equity ratio is 0.60.
Company Information
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]
Website betadrugslimited.com
CEO Mr. Rahul Batra
Employees 399
Listed 2025-11-24
Face Value ₹ 10
Issued Size 1,00,94,553
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BETA.md for Beta Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.